Journal of the American College of Cardiology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Pim1 Overexpressing ckit + Cardiac Stem  Cells in Cardiac Regeneration Preconditioning as Next-Generation Stem Cell Therapy? ∗
(Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

Pim1 Kinase Overexpression Enhances ckit + Cardiac Stem Cell Cardiac Repair Following Myocardial Infarction in Swine
BackgroundPim1 kinase plays an important role in cell division, survival, and commitment of precursor cells towards a myocardial lineage, and overexpression of Pim1 in ckit+ cardiac stem cells (CSCs) enhances their cardioreparative properties.ObjectivesThe authors sought to validate the effect of Pim1-modified CSCs in a translationally relevant large animal preclinical model of myocardial infarction (MI).MethodsHuman cardiac stem cells (hCSCs, n  = 10), hckit+ CSCs overexpressing Pim1 (Pim1+; n = 9), or placebo (n = 10) were delivered by intramyocardial injection to immunosuppressed Yorkshire swine (n = 29) 2 weeks af...
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

Truncating Variants in Filamin C The Challenges of Genotype-Phenotype Correlations in  Cardiomyopathies ∗
(Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies
ConclusionsTruncating mutations in FLNC caused an overlapping phenotype of dilated and left-dominant arrhythmogenic cardiomyopathies complicated by frequent premature sudden death. Prompt implantation of a cardiac defibrillator should be considered in affected patients harboring truncating mutations in FLNC. (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

NT-proBNP The Gold Standard Biomarker in Heart Failure ∗
(Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
ConclusionsPatients who attained a significant reduction in NT-proBNP had a lower subsequent rate of cardiovascular death or HF hospitalization independent of the treatment group. Treatment with sacubitril/valsartan was  nearly twice as likely as enalapril to reduce NT-proBNP to values ≤1,000 pg/ml. (Prospective Comparison of ARNI [Angiotensin Receptor–Neprilysin Inhibitor] with ACEI [Angiotensin-Converting–Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial) [PARA DIGM-HF]; NCT01035255.) (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

Bringing Structure to the Art of Lipid-Lowering Therapy ∗
(Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

Determining When to Add Nonstatin Therapy A Quantitative Approach
ConclusionsAdding ezetimibe or PCSK9 monoclonal antibodies to maximally tolerated statin therapy may  be cost effective in very high-risk and high-risk patients, depending on baseline LDL-C levels. (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

The Head and the Heart The Alzheimer ’s Connection ∗
(Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

A β Amyloid Pathology Affects the Hearts of Patients With Alzheimer’s Disease Mind the Heart
ConclusionsHere, the authors provide the first report of the presence of compromised myocardial function and intramyocardial deposits of A β in AD patients. The findings depict a novel biological framework in which AD may be viewed either as a systemic disease or as a metastatic disorder leading to heart, and possibly multiorgan failure. AD and HF are both debilitating and life-threatening conditions, affecting enormous patient pop ulations. Our findings underline a previously dismissed problem of a magnitude that will require new diagnostic approaches and treatments for brain and heart disease, and their combinati...
Source: Journal of the American College of Cardiology - November 29, 2016 Category: Cardiology Source Type: research

Reply Risk Scores From PARIS Registry: Are They Useful in a Contemporary Cohort of ACS Patients?
We appreciate the comments and concerns raised by Dr. Raposeiras-Roubin and colleagues regarding the PARIS (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients) risk scores for coronary thrombosis and major bleeding following percutaneous coronary intervention (PCI) with drug eluting stents that we recently reported in theJournal(1). We agree with the authors that evaluating model performance in patients with acute coronary syndrome or sustaining early events within the first year are important considerations. Accordingly, we have provided metrics of model performance according to these parameters inTab...
Source: Journal of the American College of Cardiology - November 22, 2016 Category: Cardiology Source Type: research

Risk Scores From PARIS  Registry Are They Useful in a Contemporary Cohort of ACS Patients?
We have read the recently published paper from Baber et  al.(1). We would like to congratulate the authors for their excellent work, with the aim to integrate both risks (ischemic and hemorrhagic) in the  same population. However, we have several concerns: (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 22, 2016 Category: Cardiology Source Type: research

Reply Why to Replace an ACE or ARB With  an ARB/Neprilysin Inhibitor?
The American College of Cardiology (ACC) and American Heart Association (AHA) welcome letters to inform its ongoing work and encourage such correspondence about its clinical policy statements. Because the ACC/AHA guideline development process is rigorous and involves several layers of review by the writing committee, external peer reviewers, and participating organizations endorsing the document, there is limited editorial control over the content after publication. The information, however, gleaned from questions such as this is forwarded to the writing committee chairs and oversight Task Force for review. If any issues a...
Source: Journal of the American College of Cardiology - November 22, 2016 Category: Cardiology Source Type: research

Why to Replace an ACE  or ARB With an ARB/Neprilysin Inhibitor?
In the 2016 American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America (HFSA) Focused Update on New Pharmacological Therapy for Heart Failure(1), there is a new recommendation: in patients with chronic symptomatic heart failure with reduced ejection fraction New York Heart Association functional class II or III who tolerate an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, replacement by an ARNI is recommended to further reduce morbidity and mortality, where ARNI stands for Valsartan/Sacubitril (Novartis Pharmaceuticals, East Hanover, New Jersey), an ...
Source: Journal of the American College of Cardiology - November 22, 2016 Category: Cardiology Source Type: research

Cardiac Phenotype and Long-Term Follow-Up of Patients With Mutations in NKX2-5 Gene
One of the essential homeobox transcription factors orchestrating cardiac embryologic development isNKX2-5(1). Mutations inNKX2-5 were initially discovered in inherited atrial septal defect (ASD) associated with atrioventricular block (AVB)(2), but were further found linked to other congenital heart  defects and cardiomyopathies. However, it remains difficult to have a clear idea of the cardiac abnormalities caused byNKX2-5 mutations in large populations. (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - November 22, 2016 Category: Cardiology Source Type: research